Key result
A cumulative anthracycline dose exceeding 201 mg/m2 was associated with a 4.4-fold increased odds of cardiac dysfunction (OR 4.4) in children treated for cancer.
Why the study?
Does a cumulative anthracycline dose >201 mg/m2 increase the risk of left ventricular dysfunction in pediatric oncology patients?
Cross-Sectional (n=111)
No
Does a cumulative anthracycline dose >201 mg/m2 increase the risk of left ventricular dysfunction in pediatric oncology patients?
Answers are grounded in this paper and cite their sources.
In pediatric cancer patients, a cumulative anthracycline dose above 200 mg/m2 is associated with a significantly increased risk of early left ventricular dysfunction, highlighting the need for routine serial echocardiography.
OBJECTIVE: To determine the point prevalence of abnormal cardiac function and to assess the risk factors for cardiac dysfunction in paediatric oncology patients on treatment at Kenyatta National Hospital. DESIGN: Descriptive cross-sectional study with a nested case control. SETTING: Kenyatta National Hospital between February and April 2006. MAIN OUTCOME MEASURES: Left ventricular dysfunction if ejection fraction (EF) <55% or fractional shortening (FS) <29% defined cases. Controls had EF >55% or FS >29%. RESULTS: One hundred and eleven patients were enrolled of whom 32 had abnormal cardiac function and were classified as cases while 79 had normal cardiac function. About a third, point prevalence 29% (95% CI 21.2-37.9), had cardiac dysfunction. Cumulative anthracycline dose was a risk factor for cardiac dysfunction in this population. Above 200 mg/m2 the attributable risk percentage of cardiac dysfunction was 77%. CONCLUSIONS: Serial echocardiography should be performed to identify patients at risk. Alternative treatment protocols should be used when the cumulative anthracycline dose exceeds 200 mg/m2 due to the high attributable risk. Studies to further assess the other associated risk factors and long term effects of anthracycline are recommended.
No takes yet. Share an insight, caveat, or question.
Shiroya-Wandabwa et al. (2010) conducted a cross-sectional in Childhood cancer (n=111). Cumulative anthracycline dose > 201 mg/m2 vs. Cumulative anthracycline dose ≤ 30 mg/m2 was evaluated on Left ventricular dysfunction (ejection fraction <55% or fractional shortening <29%) (OR 4.4, 95% CI 1.3-15.4, p=0.02). A cumulative anthracycline dose exceeding 201 mg/m2 was associated with a 4.4-fold increased odds of cardiac dysfunction (OR 4.4) in children treated for cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: